Showing 7 results for Neamatzadeh
Dr G Kholasehzadeh , Dr Sm Shiryazdi , Mr H Neamatzadeh , Mrs N Ahmadi ,
Volume 4, Issue 3 (9-2014)
Abstract
Background
The aim of the study was to evaluate the depression levels in mothers of children with leukemia.
Materials and Methods
This single centred, cross-sectional study was conducted among mothers of children with leukemia at the Hematology and Oncology research center, Baghaie-Pour clinic in Yazd City during February through December, 2013. The study sample included 58 mothers with 1-12 year old children with the diagnosis or treated at the Shahid Sadoughi hospital. Socio-demographic characteristics were gathered using a socio-demographic form and Beck Depression Inventory (BDI) was applied to all mothers to assess symptoms of depression. All variables that could potentially impact dependent outcome measures of the BDI were analyzed. These factors were mothers' age, mothers' education, and socioeconomic status of the family, gender of child.
Results
The analysis revealed that mothers of children leukemia had a moderate level of depression and stress, and a severe level of anxiety. 41 participants (70.6%) indicated their current depressive symptoms as being in the severe range, 12 participants (20.6%) in the moderate range, and 5 participants (8.6%) in the mild range or no depression. There was an inverse correlation between the educational level of the mothers and the heads of household, their occupational status, their marital status, their socio-economic condition and depression. The depression scores of the mothers of patients were higher than those of the controls.
Conclusion
Depression ideation is common among mothers of children with leukemia. There are strong associations with socio-economic condition and high depression levels.
R Masoumi-Dehshiri , As Hashemi , H Neamatzadeh, H Zare-Zardini ,
Volume 4, Issue 4 (12-2014)
Abstract
Acute myeloid leukemia (AML-M7) is a type of pediatric AML accounting for 3–10% of primary childhood AML and children may present with a broad variety of symptoms including low-grade fever, diarrhea, easy bruising, failure to gain weight and life-threatening conditions. We report a rare case of AML .A 26-month-old boy who presented with weakness and fatigue. He was diagnosed as a case of AMLM-7 on the basis of peripheral blood finding, bone marrow examination report and immune phenotyping.
Dr M Hashemieh, Dr H Timori Naghadeh, Dr M Tabrizi Namini, Mr H Neamatzadeh, Dr M Hadipour Dehshal,
Volume 5, Issue 3 (8-2015)
Abstract
Abstract
Background
Iran is one of the countries located on the “thalassemia belt” and a thalassemia prevention program was approved in our country in 1995. Many different
researchers have studied the success of this program with no unanimous findings.
Material and Methods
A comprehensive literature search was performed using PubMed, Web of Science, and Google Scholar databases in Farsi and English languages for relevant articles published up to March 2015.
Results
A total of 46 articles regarding thalassemia prevention were identified. After screening the titles and abstracts, 27 articles were excluded because they were the same articles, review articles, and case reports. Finally, 16 articles about the success of the Iranian thalassemia prevention program were selected for the evaluation.
Conclusion
The findings show that the program has been significantly successful in the reduction of the new thalassemia births, though not in a few provinces like Sistan and Baluchestan. The role of the network of genetic labs has been also indispensable in the reduction of the new births. However, there is ambiguity over the impact of the program on the attitude and awareness of people across the country about the prevention of inherited diseases. However, with the success of the Iran thalassemia prevention program, it needs to be modified to be more compatible with the relevant social textures of different provinces.
Mr H Zare-Zardini , Dr A Taheri-Kafrani , Dr A Amiri , Dr M Shanbedi , Mrs Z Sadri , Mrs F Ghanizadeh , Mr H Neamatzadeh , Dr R Sheikhpour, Mrs F Keyvani Boroujeni , Dr F Daneshmand,
Volume 5, Issue 4 (12-2015)
Abstract
Despite development of new approaches for the treatment of cancer disease, it is the second cause of mortality in world. Annually, 30000 persons die in Iran due to cancer diseases. Eighty percent of cancer patients are children which about 50% children lead to death. Given the high rate of cancer-related death, the new approaches for prevention, control, early diagnosis, and treatment of this disease seem necessary. Investigation of new strategies is the major challenge for scientists at recent century. Nanotechnology as a new scientific field with novel and small compounds utilized different fields over the past ten years especially in medicine. This science has come to the forefront in the areas of medical diagnostics, imaging, and therapeutic scheduls. Therefore, it has the potential applications for cancer detection and therapy. This review will discuss the therapeutic applications of different nano-materials in diagnosis, imaging, and delivery of therapeutic agents for the treatment of cancer with a major focus on their applications for the treatment of cancer and cancer- related diseases in children. The advancements in established nanoparticle technologies such as liposomes, polymer micelles, and functionalization regarding tumor targeting and controlled release strategies as well as drug delivery were discussed. It will also review the blood toxicity of used nanostructures.
Dr M Forat-Yazdi, Dr F Hosseini-Biouki, Dr J Salehi, Mr H Neamatzadeh, Dr R Masoumi Dehshiri, Mrs Z Sadri, Mrs F Ghanizadeh, Dr R Sheikhpour, Mr H Zare-Zardini,
Volume 6, Issue 1 (3-2016)
Abstract
Background
Evidence indicates RFC1 G80A polymorphism as a risk factor for a number of cancers. Increasing studies have been conducted on the association of RFC1 G80A polymorphism with acute lymphoblastic leukemia (ALL) risk. However, the results were controversial. The aim of the present study was to derive a more precise estimation of the relationship.
Materials and Method
PubMed, Embase, Web of Science, Cochrane database, and Google Scholar were searched to get the genetic association studies between RFC1 G80A polymorphism and ALL. All eligible studies for the period up to February 2016 were identified. Subgroup analyses regarding ethnicity were also implemented. All statistical analyses were done with CMA 2.0.
Results
A total of ten studies comprising of 2,168 ALL cases and 2,693 healthy controls were included in this meta-analysis. Overall, no significant association was detected for allelic model (OR = 1.029, 95 % CI 0.754- 1.405, P=0.000), Dominant model (OR = 1.619, 95 % CI 0.847-3.094, P=0.145), recessive model (OR = 1.169, 95 % CI 10.764-1.790, P=0.429), and homozygote model (OR = 1.288, 95 % CI 0.928-1.788, P=0.130). However, there was an obvious association under the heterozygote model (OR = 1.368, 95 % CI 1.056- 1.772, P=0.018). Also, in the stratified analysis by ethnicity, no significant association of this polymorphism with risk of OC was found in the Asian and Caucasian populations. However, there was not significant
heterogeneity between heterozygote genetic model (P = 0.15, I2 = 33%) in Caucasian. Therefore, we utilized the fixed-effect model to merge OR value.
Conclusion
Based on the available evidence, no association between RFC1 G80A Polymorphism and ALL risk was observed, even in the subanalysis by ethnicity. The direction of further research should focus not only on the simple relationship of RFC1 G80A Polymorphism and ALL risk, but also on gene–gene and gene-environment interaction.
Dr Mohammad Reza Sobhan, Dr Shadi Mostafavi, Dr Mahta Mazaheri, Mr Hossein Neamatzadeh,
Volume 7, Issue 2 (3-2017)
Abstract
Background: Understanding the differences in genetics of malignancies is crucial for therapeutic decisions. This systematic review was conducted to evaluate the current evidence on genetics of bone tumors in the context of pediatric cancer.
Material and Methods: We performed a systematic review of the literature published on genetics of pediatrics bone tumors, using PubMed, Google scholar, Science Citation Index and Embase. The search profiles used were: pediatric/childhood malignant bone tumors, pediatric/ childhood bone cancer/neoplasm, osteosarcoma/bone sarcoma/Ewing's sarcoma and risk factors/etiology. Inclusion criteria were as follows: focused upon biology and genetics mechanism of primary bone tumors and published in the last 15 years in English.
Results: A total of 278 articles were searched for relevancy, determined by article title, abstract, and full copy. After screening the titles and abstracts, 239 articles were excluded because they were the same articles and case reports. Finally, 39 articles were found that fulfilled all inclusion criteria.
Conclusion: This systematic review shows that many genetic studies have been performed on the genetics basis of pediatrics bone tumors. The knowledge base formed by this review should facilitate more informative future research. It is important that orthopedics and other specialists be aware about genetics basis of pediatrics bone tumors.
Dr Amirhossein Omidi, Dr Maryam Sadat Yazdanparast, Dr Seyedeh Elham Shams, Dr Reza Bahrami, Dr Mohammad Golshan-Tafti, Dr Seyed Alireza Dastgheib, Dr Maryam Yeganegi, Dr Mahsa Danaie, Dr Ali Masoudi, Dr Amirmasoud Shiri, Dr Maryam Aghasipour, Dr Kazem Aghili, Dr Mahmood Noorishadkam, Dr Hossein Neamatzadeh,
Volume 15, Issue 2 (3-2025)
Abstract
The Pediatric Buccal Epigenetic (PedBE) and Neonatal Epigenetic Estimator of Age (NEOage) clocks provide a novel method for assessing the biological age of young individuals, enhancing our comprehension of their health and development. By analyzing DNA methylation patterns, these clocks identify risk factors for various health conditions and guide personalized interventions to promote optimal growth in children and infants. With ongoing research and validation, PedBE and NEOage could revolutionize pediatric and neonatal healthcare by facilitating early detection of age-related changes and targeted interventions to improve long-term outcomes. In pediatric oncology, PedBE is particularly promising for evaluating biological age in children with cancer, as it accurately estimates DNA methylation age in buccal cells, revealing the effects of cancer and its treatments on biological aging. Additionally, PedBE can detect DNA methylation changes associated with environmental exposures and childhood adversities, making it a valuable tool for studying the impact of cancer on the epigenetic age of pediatric patients. The NEOage clock, designed to predict gestational age in newborns, complements the PedBE clock, offering a comprehensive assessment of biological age from infancy to adolescence, which is vital for understanding pediatric oncology’s influence on aging. This paper examines the complexities of both clocks, highlighting their potential for accurately determining the age of children and infants through DNA methylation analysis.
